322 related articles for article (PubMed ID: 28683005)
1. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible.
Girda E; Huang EC; Leiserowitz GS; Smith LH
Int J Gynecol Cancer; 2017 Oct; 27(8):1701-1707. PubMed ID: 28683005
[TBL] [Abstract][Full Text] [Related]
2. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
3. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
4. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
Chen H; Gotimer K; De Souza C; Tepper CG; Karnezis AN; Leiserowitz GS; Chien J; Smith LH
Gynecol Oncol; 2020 Jun; 157(3):783-792. PubMed ID: 32253045
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.
Collins A; Miles GJ; Wood J; MacFarlane M; Pritchard C; Moss E
Gynecol Oncol; 2020 Jan; 156(1):251-259. PubMed ID: 31767187
[TBL] [Abstract][Full Text] [Related]
6. Testing Susceptibility of Patient-Derived Organoid Cultures to Therapies: Pharmacotyping.
Burkhart RA; Baker LA; Tiriac H
Methods Mol Biol; 2018; 1787():253-261. PubMed ID: 29736724
[TBL] [Abstract][Full Text] [Related]
7. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues.
Tamura H; Higa A; Hoshi H; Hiyama G; Takahashi N; Ryufuku M; Morisawa G; Yanagisawa Y; Ito E; Imai JI; Dobashi Y; Katahira K; Soeda S; Watanabe T; Fujimori K; Watanabe S; Takagi M
Oncol Rep; 2018 Aug; 40(2):635-646. PubMed ID: 29917168
[TBL] [Abstract][Full Text] [Related]
9. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
10. The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo.
Schrauwen S; Coenegrachts L; Cattaneo A; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Aug; 138(2):378-82. PubMed ID: 26050920
[TBL] [Abstract][Full Text] [Related]
11. Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.
Bi J; Newtson AM; Zhang Y; Devor EJ; Samuelson MI; Thiel KW; Leslie KK
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34200645
[TBL] [Abstract][Full Text] [Related]
12. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
[TBL] [Abstract][Full Text] [Related]
13. Drug Sensitivity Assays of Human Cancer Organoid Cultures.
Francies HE; Barthorpe A; McLaren-Douglas A; Barendt WJ; Garnett MJ
Methods Mol Biol; 2019; 1576():339-351. PubMed ID: 27628132
[TBL] [Abstract][Full Text] [Related]
14. On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study.
Sailer V; Pauli C; Merzier EC; Mosquera JM; Beltran H; Rubin MA; Rao RA
Anticancer Res; 2017 Apr; 37(4):1569-1573. PubMed ID: 28373416
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
Byron SA; Loch DC; Pollock PM
Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
[TBL] [Abstract][Full Text] [Related]
16. Hydrogel-based colorectal cancer organoid co-culture models.
Luo X; Fong ELS; Zhu C; Lin QXX; Xiong M; Li A; Li T; Benoukraf T; Yu H; Liu S
Acta Biomater; 2021 Sep; 132():461-472. PubMed ID: 33388439
[TBL] [Abstract][Full Text] [Related]
17. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of multiple patient-derived organoids from a case of advanced endometrial cancer.
Maru Y; Kohno M; Suzuka K; Odaka A; Masuda M; Araki A; Itami M; Tanaka N; Hippo Y
Hum Cell; 2024 May; 37(3):840-853. PubMed ID: 38546950
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank for high-throughput and high-content drug screening.
Luo Z; Wang B; Luo F; Guo Y; Jiang N; Wei J; Wang X; Tseng Y; Chen J; Zhao B; Liu J
BMC Med; 2023 Sep; 21(1):336. PubMed ID: 37667332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
